NASDAQ · INTS
Intensity Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for INTS: Nov 5, 2026
Intensity Therapeutics, Inc. Common stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.94. The reported EPS for the same quarter last year was $-1.5.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.94 | $-0.77 | $-1.11 | 2 |
| Dec 2026 | $-0.45 | $-0.20 | $-0.71 | 2 |
| Mar 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Jun 2027 | $-0.22 | $-0.22 | $-0.22 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Zacks · Fintel- RTTNews · Sep 4, 8:22 AM EDTIntensity's Q2 Loss Widens Marginally As Trials For Breast Cancer Drug Resume(RTTNews) – Intensity Therapeutics Inc. (INTS), a late-stage clinical biotechnology company, recently announced financial results for the second quarter and attributed a slightly wider loss due to an increase in clinical research expenses.
- The Motley Fool · Aug 11, 9:57 PM EDTIntensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- RTTNews · Aug 4, 2:22 AM EDTCue Biopharma Appoints Ahlers As CFO Following IND Filing And Pipeline Progress(RTTNews) – Cue Biopharma, Inc. (CUE), a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, announced the appointment of James Ahlers as Chief Financial Officer (CFO), effective immediately.
- RTTNews · Jul 17, 11:05 AM EDTIntensity Resumes Phase 2 INVINCIBLE-4 Study For INT230-6 In Breast Cancer With Lower Dose(RTTNews) – Intensity Therapeutics Inc. (INTS), a late-stage clinical biotechnology company, on Wednesday announced the resumption of the Phase 2 INVINCBLE-4 trial for INT230-6 in treating triple-negative breast cancer.
- Zacks · May 27, 12:00 PM EDTIntensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's WhyIntensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks · May 1, 9:55 AM EDTIntensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock NowIntensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Zacks · Apr 16, 12:00 PM EDTIntensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should KnowIntensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Mar 12, 8:30 AM EDTIntensity Reports Strong Early Tumor-Clearance Signal In INVINCIBLE-4 Study(RTTNews) – Intensity Therapeutics, Inc. (INTS) reported encouraging early results from its Phase 2 INVINCIBLE-4 presurgical study in triple-negative breast cancer (TNBC), with patients receiving INT230-6 before standard therapy showing notably higher complete tumor-response rate
- Fintel · Feb 25, 5:48 PM ESTIntensity Therapeutics (INTS) Price Target Increased by 2,399.98% to 74.38The average one-year price target for Intensity Therapeutics (NasdaqCM:INTS) has been revised to $74.38 / share. This is an increase of 2,399.98% from the prior estimate of $2.98 dated February 1, 2026. The price target is an average of many targets provided b
- RTTNews · Feb 9, 4:58 AM ESTIntensity Therapeutics Gains Attention – Stock Up 8%(RTTNews) – Intensity Therapeutics, Inc. (INTS), a late-stage clinical biotechnology company developing intratumoral cancer therapies using its proprietary DfuseRx technology, is up over 8% in premarket trading on Monday. The company has significant catalysts to watch during the
- Zacks · Dec 15, 12:00 PM ESTAll You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to BuyIntensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- The Motley Fool · Aug 7, 4:57 PM EDTIntensity (INTS) Q2 Net Loss Drops 50%Research and development spending was $1.5 million (GAAP), This amount represents a decrease of approximately 58% year-over-year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Intensity Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.